Update and review: Cystic fibrosis

Journal of Genetic Counseling

Volumn 8, Issue 3, 1999, Pages 137-162

  Brown, Trisha ^a   Schwind, Elinor Langfelder ^b  

^a LABORATORY CORPORATION OF AMERICA   (United States)

^b ST VINCENT S HOSPITAL   (United States)

Author keywords

Cystic fibrosis; Genetic counseling; Genotype phenotype

Indexed keywords

BRONCHIECTASIS; CYSTIC FIBROSIS; GENE FUNCTION; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IDIOPATHIC DISEASE; MUTATION; PANCREATITIS; PHENOTYPE; RECESSIVE INHERITANCE; REVIEW; VAS DEFERENS;

EID: 0033006407     PISSN: 10597700     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022853822424     Document Type: Review

References (168)

1. Abeliovich D, Lavon IP, Lerer I, Cohen T, Springer C, Avital A, Cutting GR (1992) Screening for five mutations detects 97% of cystic fibrosis (CF) chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am J Hum Genet 51:951-956.
2. Allitto BA, Treat K (1998) Personal communication.
3. Andersen HO, Hjelt K, Waever E, Overgaard K (1990) The age-related incidence of meconium ileus equivalent in a cystic fibrosis population: The impact of high-energy intake. J Pediatr Gastroenterol Nutr 11:356-360.
4. Anguiano A, Oates RD, Amos JA, Dean M, Gerrard B, Stewart C, Maher TA, White MB, Milunsky A (1992) Congenital bilateral absence of the vas deferens: A primarily genital form of cystic fibrosis. JAMA 267:1794-1797.
5. Arispe N, Ma J, Jacobson KA, Pollard HB (1998) Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX). J Biol Chem 273:5727-5734.
6. Asch DA, Hershey JC, Dekay ML, Pauly MV, Patton JP, Jedrziewski MK, Frei F, Giardine R, Kant JA, Mennuti MT (1998) Carrier screening for cystic fibrosis: Costs and clinical outcomes. Med Decis Making 18:202-212.
7. Augarten A, Kerem BS, Yahav Y, Noiman S, Rivlin Y, Tal A, Blau H, Ben-Tur L, Szeinberg A, Kerem E, Gazit E (1993) Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C-to-T mutation. Lancet 342:25-26.
8. Axworthy D, Brock DJ, Bobrow M, Marteau TM (1996) Psychological impact of population-based carrier testing for cystic fibrosis: 3-year follow-up, UK Cystic Fibrosis Follow-Up Study Group. Lancet 347:1443-1446.
9. Barasch J, Kiss B, Prince A, Saiman L, Gruenert D, al-Awqati Q (1991) Defective acidification of intracellular organelles in cystic fibrosis. Nature 352:70-73.
10. Bekker H, Denniss G, Modell M, Bobrow M, Marteau T (1994) The impact of population based screening for carriers of cystic fibrosis. J Med Genet 31:364-368.
11. Bekker H, Modell M, Denniss G, Silver A, Mathew C, Bobrow M, Marteau T (1993) Uptake of cystic fibrosis testing in primary care: Supply push or demand pull? BMJ 306:1584-1586.
12. Berkin KE, Alcock SR, Stack BH (1985) Cystic fibrosis - A review of 26 adolescent and adult patients. Eur J Respir Dis 67:103-111.
13. Blair C, Kacser E, Porteous D (1998) Gene therapy for cystic fibrosis: A psychosocial study of trial participants Gene Ther 5:218-222.
14. Boat TF, Welsh MJ, Beaudet AL (1989) Cystic fibrosis in Scriver CR, Beaudet AL, Sly WS, Valle D, The Metabolic Basis of Inherited Disease, Chapter 108, pp. 2649-2680.
15. Borgo G, Fabiano T, Mastella P, Mastella G (1992) Effect of introducting prenatal diagnosis on the reporductive behaviour of families at risk for cystic fibrosis: A cohort study. Prenatal Diag 12:821-830.
16. Boue J, Muller F, Simon-Bouy B, Faure C, Boue A (1991) Consequences of prenatal diagnosis of cystic fibrosis on the reproductive attitudes of parents of affected children. Prenatal Diag 11:209-214.
17. Bradbury NA, Jilling T, Berta G, Sorscher EJ, Bridges RJ, Kirk KL (1992) Regulation of plasma membrane recycling by CFTR. Science 256:530-532.
18. Brock DJ (1996) Prenatal screening for cystic fibrosis: 5 years' experience reviewed. Lancet 347:148-150.
19. Brown, T (1998) Personal observation.
20. Burger J, Macek M. Jr, Stuhrmann M, Reis A, Krawczak M, Schmidtke J (1991) Genetic influences in the formation of nasal polyps. Lancet 337:974.
21. Canny GJ, Corey M, Livingstone RA, Carpenter S, Green L, Levison H (1991) Pregnancy and cystic fibrosis. Obstet Gynecol 77:850.
22. Casavola V, Turner RJ, Guay-Broder C, Jacobson KA, Eidelman O, Pollard HB (1995) CPX, a selective Al-adenosine-receptor antagonist, regulates intracellular pH in cystic fibrosis cells. Am J Physiol 269:C226-233.
23. Castaldo G, Rippa E, Salvatore D, Sibillo R, Raia V, de Ritis G, Salvatore F (1997) Severe liver impairment in a cystic fibrosis-affected child homozygous for the G542X mutation. Am J Med Genet 69:155-158.
24. Castellani C, Bonizzato A, Mastella G (1997) CFTR mutations and IVS8-5T variant in newboms with hypertyprsinaemia and normal sweat test. J Med Genet 34:297-301.
25. Cheadle J, Al-Jader L, Goodchild M, Meredith AL (1992) Mild pulmonary disease in a cystic fibrosis child homozygous for R553X. J Med Genet 29:597.
26. Cheuvront B, Sorenson JR, Callanan N, Stearns SC, DeVillis BM (1998) Psychosocial and educational outcomes associated with home- and clinic-based pretest education and cystic fibrosis carrier testing among a population of at-risk relatives. Am J Med Genet 75:461-468.
27. Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, Romey MC, Ruiz-Romero J, Verlingue C, Claustres M, Nunes V, Ferec C, Estivill X (1995) Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferons. N Engl J Med 332:1475-1480.
28. Christ MJ, Iwamoto LM, de Silva A, Lavallee SL, Nakamura KT (1998) Amiloride-induced contraction of isolated guinea pig, mouse, and human fetal airways. Am J Physiol 274:R209-R213.
29. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG (1993) Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nature Genet 3:151-156.
30. Chu CS, Trapnell BC, Murtagh JJ, Moss J, Dalemans W, Jallat S, Mercenier A, Pavirani A, Lecocq JP, Cutting GR, Guggino WB, Crystal RG (1991) Variable detection of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. EMBO J 10:1355-1363.
31. Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW 3rd, Phillips JA 3rd (1995) Teaching about cystic fibrosis carrier screening by using written and video information. Am J Hum Genet 57:171-181.
32. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowelt PS (1998) Relation between mutations of the cystic fibrosis gene and iopathic pancreatitis. N Engl J Med 339:653-658.
33. Correlation between genotype and phenotype in patients with cystic fibrosis (1993) The Cystic Fibrosis Genotype-Phenotype Consortium. Engl J Med 329:1308-1313.
34. Corteville JE, Gray DL, Langer JC (1996) Bowel abnormalities in the fetus - Correlation of prenatal ultrasonographic findings with outcome. Am J Obstet Gynecol 175:724-729.
35. Costes B, Girodon E, Ghanem N, Flori E, Jardin A, Soufir JC, Goossens M (1995) Frequent occurrence of the CFTR intron 8 (TG)n 5T allele in men with congenital bilateral absence of the vas deferens. Europ J Hum Genet 3:285-293.
36. Cowen L, Mok J, Corey M, MacMillan H, Simmons R, Levison H (1986) Psychologic adjustment of the family with a member who has cystic fibrosis. Pediatrics 77:745-753.
37. Crystal RG, Mastrangeli A, Sanders A, Cooke J, King T, Gilbert F, Henschke C, Pascal W, Herena J, Harvey BG (1995) Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis. Human Gene Therapy 6:667-703.
38. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C (1994) Administration of an adenovirus containing the humanCFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet 8:42-51.
39. Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, Jorissen M, Droogmans G, Reynaert I, Goossens M, Nilius B, Cassiman JJ (1998) Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes: the polymorphic (TG)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 101:487-496.
40. Cuppens H, Marynen P, De Boeck C, De Baets F, Eggermont E, Van den Berghe H, Cassiman JJ (1990) A child, homozygous for a stop codon in exon 11, shows milder cystic fibrosis symptoms than her heterozygous nephew. J Med Genet 27:717-719.
41. Curtis A, Nelson R, Porteous M, Burn J, Bhattacharya SS (1991) Association of less common cystic fibrosis mutations with a mild phenotype. J Med Genet 28:34-37.
42. Curtis JR, Burke W, Kassner AW, Aitken ML (1997) Absence of health insurance is associated with decreased life expectancy in patients with cystic fibrosis. Am J Respir Care Med 155:1921-1924.
43. Cutting GR, Kasch LM, Rosenstein BJ, Zielenski J, Tsui LC, Antonarakis SE, Kazazian HH Jr. (1990) A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature 346:366-369.
44. The Cystic Fibrosis Foundation. (1997) Clinical Practice Guidelines for Cystic Fibrosis. Bethesda, MD.
45. The Cystic Fibrosis Foundation (1998) Annual Patient Registry Data. Bethesda, MD.
46. Cystic Fibrosis Mutation Data Base. Collected by the Cystic Fibrosis Genetic Analysis Consortium (1998) http://www.genet.sickkids.on.ca/cftr/.
47. Delaney SJ, Alton EW, Smith SN, Lunn DP, Farley R, Lovelock PK, Thomson SA, Hume DA, Lamb D, Porteous DJ, Dorin JR, Wainwright BJ (1996) Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. EMBO 15:955-963.
48. Dicke JM, Crane JP (1992) Sonographically detected hyperechoic fetal bowel: Significance and implications for pregnancy management. Obstet Gynecol 80:778-782.
49. Dork T, Dworniczak B, Auhlehla-Scholz C, Wieczorek D, Bohm I, Mayerova A, Seydewitz H, Nieschlag E, Meschede D, Horst J, Pander HJ, Sperling H, Ratjen F, Passarge E, Schnidtke J, Stuhrmann M (1997) Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens. Hum Genet 100:365-377.
50. Dreyfus DH, Bethel R, Gelfand EW (1996) Cystic fibrosis 3849+ 10kb C>T mutation associated with severe pulmonary disease and male fertility. Am J Respir Crit Care Med 153:858-860.
51. Dumur V, Gervais R, Rigot JM, Delomel-Vinner E, Decaestecker B, Lafitte JJ, Roussel P (1996) Congenital bilateral absence of the vas deferens (CBAVD) and cystic fibrosis transmembrane regulator (CFTR): Correlation between genotype and phenotype. Hum Genet 97:7-10.
52. Dumur V, Lafitte JJ, Gervais R, Debaecker D, Kesteloot M, Lalau G, Roussel P (1990) Abnormal distribution of cystic fibrosis delta-F508 allele in adults with chronic bronchial hypersecretion. Lancet 335:1340.
53. Estivill X, Bancells C, Ramos C (1997) Geographic distribution and regional origin of 272 cystic fibrosis mutaitons in european populations: The Biomed CF Mutation Analysis Consortium. Hum Mutât 10:135-154.
54. Evers-Kiebooms G, Denayer L, Van den Berghe H (1990) A child with cystic fibrosis: 2. Subsequent family planning decisions, reproduction and use of prenatal diagnosis. Clin Gen 37:207-215.
55. Faden RR, Tambor ES, Chase GA, Geller G, Hofman KJ, Holtzman NA ( 1994) Attitudes of physicians and genetics professionals toward cystic fibrosis carrier screening. Am J Med Genet 50:1-11.
56. Fanos JH, Johnson JP (1995) Barriers to carrier testing for adult cystic fibrosis sibs: The importance of not knowing. Am J of Med Gen 59:85-91.
57. Farrell PM, Kosorok MR, Laxova A, Shen G, Koscik RE, Bruns T, Splaingard M, Mischler EH (1997) Nutritional benefits of neonatal screening for cystic fibrosis. N Engl J Med 337:963-969.
58. Ferkol T, Pellicena-Palle A, Eckman E, Perales JC, Trzaska T, Tosi M, Redline R, Davis PB (1996) Immunologie responses to gene transfer into mice via the polymeric immunoglobulin receptor. Gene Ther 3:669-678.
59. Fiel SB (1996) Pulmonary function during pregnancy in cystic fibrosis: Implications for counseling. Current Opinion in PuI Med 2:462-465.
60. FitzSimmons SC, Burkhart GA, Borowitz D, Grand RJ, Hammerstrom T, Dune P (1997) High-dose pancreatic enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. New Engl J Med 336:1283-1289.
61. Franklin, C (1998) Personal communication.
62. Friedman KJ, Heim RA, Knowles MR, Silverman LM (1997) Rapid characterization of the variable length polythymidine tract in the cystic fibrosis (CFTR) gene: Association of the 5T allele with selected CFTR mutations and its incidence in atypical sinopulmonary disease. Hum Mut 10:108-115.
63. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME (1994) Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis: The Pulmozyme Study Group. N Engl J Med 331:637-642.
64. Gaillard DA, Carre-Pigeon F, Lallemand A (1997) Normal vas deferens in fetuses with cystic fibrosis. J Urol 158:1549-1552.
65. Candy, A. (1994) Pediatric Database: PEDBASE. http://icondata.com.health/pedbase/files/CYSTICFI. HTM.
66. Genetic Testing for Cystic Fibrosis, NIH Consensus Statement (1997) 15:1-37.
67. Girodan E, Cazeneuve C, Lebargy F, Chinet T, Costes B, Ghanem N, Martin J, Lemay S, Scheid P, Housset B, Bignon J, Goossens M (1997) CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 5:149-155.
68. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM (1997) Human beta-defensin-1 is asalt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553-560.
69. Grebe TA, Seltzer WK, DeMarchi J, Silva DK, Doane WW, Gozal D, Richter SF, Bowman CM, Norman RA, Rhodes SN (1994) Genetic analysis of Hispanic individuals with cystic fibrosis. Am J Hum Genet 54:443-446.
70. Grignon A, Dubois J, Quellet MC, Garel L, Oligny LL, Potier M ( 1997) Echogenic dilated bowel loops before 21 weeks' gestation: A new entity. AJR Roentgenol 168:833-837.
71. Grody WW, Dunkel-Schetter C, Tatsugawa ZH, Fox MA, Fang CY, Cantor RM, Novak JM, Bass HN, Crandall BF (1997) PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population. Am J Hum Genet 60:935-947.
72. Guillermit H, Fanen P, Ferec C (1990) A 3-prime splice site consensus sequence mutation in the cystic fibrosis gene. Hum Genet 85:450-453.
73. Guillermit H, Jehanne M, Quere I, Audrezet MP, Mercier B, Ferec C ( 1993) A novel mutation in exon 3 of the CFTR gene. Hum Genet 91:233-235.
74. Hamosh A, King TM, Rosenstein BJ, Corey M, Levison H, Durie P, Tsui LC, McIntosh I, Keston M, Brock DJH, Macek M Jr, Zemkova D, Krasnicanova H, Vavrova V, Macek M Sr, Golder N, Schwarz MJ, Super M, Watson EK, Williams C, Bush A, O'Mahoney SM, Humphries P, DeArce MA, Reis A, Burger J, Stuhrmann M, Schmidtke J, Wulbrand U, Dork T, Tummler B, Cutting GR (1992) Cystic fibrosis patients bearing both the common missense mutation gly-to-asp at codon 551 and the delta-F508 mutation are clinically indistinguishable from delta-F508 homozygotes, except for decreased risk of meconium ileus. Am J Hum Genet 51:245-250.
75. Hamosh A, Trapnell BC, Zeitlin PL, Montrose-Rafizadeh C, Rosenstein BJ, Crystal RG, Cutting GR (1991) Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. J Clin Invest 88:1880-1885.
76. Hardin DS, LeBlanc A, Lukenbough S, Seilheimer DK (1997) Insulin resistance is associated with decreased clinical status in cystic fibrosis. J Pediatr 130:948-956.
77. Hartley NE, Scotcher D, Harris H, Williamson P, Wallace A, Craufurd D, Harris R (1997) The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet 34:459-464.
78. Heine RG, Button BM, Olinsky A, Phelan PD, Catto-Smith AG (1998) Gastro-oesophageal reflux in infants under 6 months with cystic fibrosis. Arch Dis Child 78:44-48.
79. Highsmith WE, Burch LH, Boat TF, Boucher RC, Silverman LM, Knowles MR (1991) Identification of a homozygous point mutationin intron 19 in an inbred CF patient with mild disease and normalsweat chloride: creation of an alternative splice site resulting inbase-sequence insertion in CFTR coding region between exons 19 and 20. (Abstract) Pediat Pulmonol Suppl 6:22.
80. Howard M, Frizzell RA, Bedwell DM (1996) Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2:461-469.
81. Hudson VL, Guill MF (1998) New developments in cystic fibrosis. Pediatr Ann 27:515-520.
82. Hyde SC, Gill DR, Higgins CF, Trezise AEO, MacVinish LJ, Cuthbert AW, Ratcliff R, Evans MJ, Colledge WH (1993) Correction of the ion transport defect in cystic fibrosistransgenic mice by gene therapy. Nature 362:250-255.
83. Irving RM, McMahon R, Clark R, Jones NS (1997) Cystic fibrosis transmembrane conductance regulator gene mutations in severe nasal polyposis. Clin Otolaryngol 22:519-521.
84. Johnson LG (1995) Gene therapy for cystic fibrosis. Chest 107:77S-83S.
85. Kazazian H (1994) Population variation of common cystic fibrosis mutations: The Cystic Fibrosis Genetic Analysis Consortium. Hum Mutat 4:167-177.
86. Kerem B, Buchanan JA, Durie P, Corey ML, Levison H, Rommens JM, Buchwald M, Tsui LC (1989) DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. Am J Hum Genet 44:827-834.
87. Kerem E, Rave-Harel N, Augarten A, Madgar I, Nissim-Rafinia M. Yahav Y, Goshen R, Bentur L, Rivlin J, Aviram M, Genem A, Chiba-Falek O, Kraemer M, Simon A, Branski D, Kerem B (1997) A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Crit Care Med 155:1914-1920.
88. Kerem B, Zielenski J, Markiewicz D, Bozon D, Gazit E,Yahav J, Kennedy D, Riordan JR, Collins FS, Rommens JM, Tsui LC (1990) Identification of mutations in regions correspondingto the 2 putative nucleotide (ATP)-binding folds of the cystic fibrosisgene. Proc Nat Acad Sci 87:8447-8451.
89. Kiesewetter S, Macek M, Jr. Davis C, Curristin SM, Chu CS, Graham C, Shrimpton AE, Cashman SM, Tsui LC, Mickle J, Amos J, Highsmith WE, Shuber A, Witt DR, Crystal RG, Cutting GR (1993) A mutation in CFTR produces different phenotypes depending on chromosomal background. Nature Genet 5:274-278.
90. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, Leigh MW, Engelhardt JF, Edwards LJ, Jones KR, Grossman M, Wilson JM, Johnson LG, Boucher RC (1995) A controlled study of adenoviral-vector-mediated gene transferin the nasal epithelium of patients with cystic fibrosis. N Eng J Med 333:823-831.
91. Konstan MW (1998) Therapies aimed at airway inflammation in cystic fibrosis. Clin Chest Med 19:505-513.
92. Konstan MW, Byard PJ, Hoppel CL, Davis PB (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332(13):848-854.
93. Lai HC, Kosorok MR, Sondel SA, Chen ST, FitzSimmons SC, Green CG, Shen G, Walker S, Farrell PM (1998) Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: Evaluation of various criteria used to identify malnutrition. J Pediatr 132:478-485.
94. Langfelder E, Walker P, Purdy A and Berdella M (1998) Fathers with CF: Success stories (Abstract). Twelfth Annual North American Cystic Fibrosis Conference, Montreal, Canada.
95. Laroche D, Travert G (1991) Abnormal frequency of delta F508 mutation in neonatal transitory hypertrypsinaemia. Lancet 337:55.
96. Leung SS, Steinbeck KS, Morris SL, Kohn MR, Towns SJ, Bennett DL (1997) Chronic illness perception in adolescence: Implications for the doctor-patient relationship. J Paediatr Child Health 33:107-112.
97. Levenkron JC, Loader S, Rowley PT (1997) Carrier screening for cystic fibrosis: Test acceptance and one year follow-up. Am J Med Genet 73:378-386.
98. LiPuma JJ (1998) Burkholderia cepacia: Management issues and new insights. Clin Chest Med 19:473-486.
99. Logan J, Hiestand D, Daram P, Huang Z, Muccio DD, Hartman J, Haley B, Cook WJ, Sorscher FJ (1994) Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. J Clin Invest 94:228-236.
100. MacGregor SN, Tamura R, Sabbagha R, Brenhofer JK, Kambich MP, Pergament E (1995) Isolated hyperechoic fetal bowel: Significance and implications for management. Am J Obstet Gynecol 173:1254-1258.
101. Marino CR, Matovcik LM, Gorelick FS, Cohn JA (1991) Localization of the cystic fibrosis transmembrane conductance regulator in pancreas. J Clin Invest 88:712-716.
102. Marshall BC, Samuelson WM (1998) Basic therapies in cystic fibrosis: Does standard therapy work? Clin Chest Med 19:487-504.
103. Mennie ME, Axworthy D, Liston WA, Brock DJ (1997) Prenatal screening for cystic fibrosis carriers: Does the method of testing affect the longer-term understanding and reproductive behaviour of women? Prenat Diagn 17:853-860.
104. Mennie ME, Compton ME, Gilfillan A, Liston WA, Pullen I, Whyte DA, Brock DJ (1993a) Prenatal screening for cystic fibrosis: Psychological effects on carriers and their partners. J Med Genet 30:543-548.
105. Mennie ME, Gilfillan A, Compton ME, Liston WA, Brock DJ (1993b) Prenatal cystic fibrosis carrier screening: Factors in a woman's decision to decline testing. Prenat Diagn 13:807-814.
106. Meschede D, Eigel A, Horst J, Nieschlang E (1993) Compound heterozygosity for the ΔF508 and F508C cystic fibrosis transmembrane conductance regulator (CFTR) mutations in a patient with congenital bilateral aplasia of the vas deferens. Am J Hum Genet 53:292-283.
107. Miedzybrodzka Z, Semper J, Shackley P, Abdalla M, Donaldson C (1995a) Stepwise or couple antenatal carrier screening for cystic fibrosis? Women's preferences and willingness to pay. J Med Genet 32:282-283.
108. Miedzybrodzka ZH, Hall MH, Mollison J, Templeton A, Russell IT, Dean JC, Kelly KF, Marteau TM, Haltes NE ( 1995b) Antenatal screening for carriers of cystic fibrosis: Randomised trial of stepwise v couple screening. BMJ 310:353-357.
109. Millace, Warwick WJ (1998) Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 113:1230-1234.
110. Mischler EH, Wilfond BS, Post N, Laxova A, Reiser C, Sauer CM, Makholm LM, Shen G, Feenan L, McCarthy C, Farrell PM (1998) Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. Pediatrics 102:44-52.
111. Mitchell-Heggs P, Mearns M, Batten JC (1976) Cystic fibrosis in adolescents and adults. Q J Med 45: 479-504.
112. Mulivor RA, Cook D, Muller F, Boue A, Gilbert F, Mennuti M, Pergament E, Potier M, Nadler H, Punnett H, Harris, H (1987) Analysis of fetal intestinal enzymes in amniotic fluid for the prenatal diagnosis of cystic fibrosis. Am J Hum Genet 40:131-146.
113. Muller F, Dommergues M, Aubry MC, Sino-Bouy B, Gautier E, Oury JF, Narcy F (1995) Hyperechogenic fetal bowel: An ultrasonographic marker for adverse fetal and neonatal outcome. Am Obstet Gynecol 173:508-513.
114. Muller F, Dommergues M, Simon-Bouy B, Ferec C, Oury JF, Aubry MC, Bessis R, Vuillard E, Denamur E, Bienvenu T, Serre JL (1998) Cystic fibrosis screening: a fetus with hyperechogenic bowel may be the index case. J Med Genet 35:657-660.
115. Newborn Screening Fact Sheets, American Academy of Pediatrics (1996) Pediatrics 98:467-472.
116. Noone PG, Regnis JA, Liu X, Brouwer KL, Robinson M, Edwards L, Knowles MR (1997) Airway deposition and clearance and sytemic pharmokinetics of amiloride following aerolization with a ultronic nebulizer to normal airways. Chest 112:1283-1290.
117. O'Neal WK, Beaudet AL (1994) Somatic gene therapy for cystic fibrosis. Hum Mol Genet 3 Spec No: 1497-1502.
118. Osborne L, Knight R, Santis G, Hudson M (1991) A mutation in the second nucleotide binding fold of the cystic fibrosis gene. Am J Hum Genet 48:608-612.
119. Osborne L, Santis G, Schwarz M, Klinger K, Dork T, McIntosh I, Schwartz M, Nunes V, Macek M, Jr. Reiss J (1992) Incidence and expression of the N1303K mutation of the cystic fibrosis (CFTR) gene. Hum Genet 89:653-658.
120. Pan CQ, Lazarus RA (1998) Hyperactivity of human DNase I variants: Dependence on the number of positively charged residues and concentration, length, and environment of DNA Biol Chem 273:11701-11708.
121. Pauer HU, Hinney B, Michelmann HW, Krasemann EW, Zoll B, Engel W (1997) Relevance of genetic counselling in couples prior to intracytoplasmic sperm injection. Hum Reprod 12:1909-1912.
122. Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC (1998) Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J of Virology 72:6014-6023.
123. Pier GB, Grout M, Zaidi TS, Goldberg JB (1996b) How mutant CFTR may contribute to Pseudomonas aeruginosa infection in cystic fibrosis. Am J Respir Crit Care Med 154:S175-S182.
124. Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG, Yankaskas JR, Goldberg JB (1996a) Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271:64-67.
125. Pignatti PF, Bombieri C, Benetazzo M, Casartelli A, Trabetti E, Gile LS, Martinati LC, Boner AL, Luisetti M (1996) CFTR gene variant IVS8-5T in disseminated bronchiectasis. Am J Hum Genet 58:889-892.
126. Position Statements: Cystic Fibrosis (1993) National Society of Genetic Counselors.
127. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis: Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340:23-30.
128. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL (1989) Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 245:1066-1073.
129. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N (1989) Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science 245:1059-1065.
130. Rosenecker J, Schmalix WA, Schindelhauer D, Plank C, Reinhardt D (1998) Towards gene therapy of cystic fibrosis. Eur J Med Res 3:149-156.
131. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L, Pemcaudet M, Guggino WB, Pavirani A, Lecocq JP, Crystal RG (1992) In vivo transfer of the humancystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68:143-155.
132. Rosenstein BJ, Cutting GR (1998) The diagnosis of cystic fibrosis: A consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132:589-595.
133. Rowley P, Loader S, Levenkron JC (1997) Cystic fibrosis carrier population screening: A review. Genet Testing 1:53-59.
134. Rozmahel R, Wilschanski M, Matin A, Plyte S, Oliver M, Auerbach W, Moore A, Forstenr J, Dune P, Nadeau J, Bear C, Tsui LC ( 1996) Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 12:280-287.
135. Rubenstein RC, Zetlin PL (1998) A pilot clinical trial of oral sodium 4-pheylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients:partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 157:484-490.
136. Schwiebert EM, Egan ME, Hwang TH, Fulmer SB, Allen SS, Cutting GR, Guggino WB (1995) CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell 81:1063-1073.
137. Scioscia AL, Pretorius DH, Budorick NE, Cahill TC, Axelrod FT, Leopold GR(1992) Second-trimester echogenic bowel and chromosomal abnormalities. Am J Obstet Gynecol 167:889-894.
138. Sepulveda W, Leung KY, Robertson ME, Kay E, Mayall, ES, Fisk NM (1996) Prevalence of cystic fibrosis mutations in pregnancies with fetal echogenic bowel. Obstet Gynecol 87:103-106.
139. Sharer N, Schwarz M, Maline G, Howarth A, Painter J, Super M, Braganza J (1998) Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 339:645-652.
140. Shoshani T, Augarten A, Gazit E, Bashan N, Yahav Y, Rivlin Y, Tal A, Seret H, Yaar L, Kerem E, Kerem B (1992) Association of a nonsense mutation (WI282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet 50:222-228.
141. Shoshani T, Kerem E, Szeinberg A, Augarten A, Yahav Y, Cohen D, Rivlin J, Tal A, Kerem BS (1994) Similar levels of mRNA from the W1282X and the delta-F508 cystic fibrosis alleles in nasal epithelial cells. J Clin Invest 93:1502-1507.
142. Sipes SL, Weiner CP, Wenstrom KD, Williamson RA, Grant SS, Mueller GM (1994) Fetal echogenic bowel on ultrasound: Is there clinical significance? Fetal Diagn Ther 9:38-43.
143. Slotnick RN, Abuhamad AZ (1996) Prognostic implications of fetal echogenic bowel. Lancet 347:85-87.
144. Snell GI, de Hoyos A, Krajden M, Winton T, Maurer JR (1993) Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 103:466-471.
145. Starnes VA, Barr ML, Cohen RG, Hagen JA, Wells WJ, Horn MV, Schenkel FA (1996) Living-donor lobar lung transplantation experience: intermediate results. J Thorac Cardiovasc Surg 112:1284-1290.
146. Statement on Genetic Testing for Cystic Fibrosis (1997) American College of Medical Genetics.
147. Stevens JC, Maguiness KM, Hollingsworth J, Heilman DK, Chong SK (1998) Pancreatic enzyme supplementation in cystic fibrosis patients before and after fibrosing colonopathy. J Pediatr Gastroenterol Nutr 26:80-84.
148. Stutts MJ, Rossier BC, Boucher RC (1997) Cystic fibrosis transmembrane conductance regulator inverts protein kinase A-mediated regulation of epithelial sodium channel single channel kinetics. J Biol Chem 272:14037-14040.
149. Tambor ES, Bernhardt BA, Chase GA, Faden RR, Geller G, Hofman KJ, Holtzman NA (1994) Offering cystic fibrosis carrier screening to an HMO population: Factors associated with utilization. Am J Hum Genet 55:626-637.
150. Teng H, Jorissen M, Van Poppel H, Legius E, Cassiman JJ, Cuppens H (1997) Increased proportion of exon 9 alternatively spliced CFTR transcripts in vas deferens compared with nasal epithelial cells. Hum Molec Genet 6:85-90.
151. Teramoto S, Bartlett JS, McCarty D, Xiao X, Samulski RJ, Boucher RC (1998) Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: Comparison with adenovirus vectors. J Virol 72:8904-8912.
152. Trapnell BC, Chu CS, Paakko PK, Banks TC, Yoshimura K, Ferrans VJ, Chernick MS, Crystal RG (1991) Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis. Proc Nat Acad Sci 88:6565-6569.
153. Tsui L, Dune P (1997) Genotype and phenotype in cystic fibrosis. Hosp Prac June 115-142.
154. United Network for Organ Sharing (1997) Annual Report. www.UNOS.org.
155. Verlinsky Y, Rechitsky S, Cieslak J, Ivakhnenko V, Wolf G, Lifchez A, Kaplan B, Moise J, Walle J, White M, Ginsberg N, Strom C, Kuliev A (1997) Preimplantation diagnosis of single gene disorders by two-step oocyte genetic analysis using first and second polar body. Biochem Mol Med 62:182-187.
156. Vintzileos AM, Ananth CV, Smulian JC, Fisher AJ, Day-Salvatore D, Beazoglou T (1998) A cost-effectiveness analysis of prenatal carrier screening for cystic fibrosis. Obstet Gynecol 91:529-534.
157. Watson EK, Marchant J. Bush A, Williamson B (1992) Attitudes towards prenatal diagnosis and carrier screening for cystic fibrosis among the parents of patients in a paediatric cystic fibrosis clinic. J Med Genet 29:490-491.
158. Watson EK, Williamson R, Chappie J (1991) Attitudes to carrier screening for cystic fibrosis: A survey of health care professionals, relatives of sufferers and other members of the public. Br J Gen Pract 41:237-240.
159. Waurin J (1998) Personal communication.
160. Weisemann HG, Steinkamp G, Ratgen F, Bauernfeind A, Przyklenk B, Doling G, von der Hardt H (1998) Placebo controlled, double blind randomized study of aerosolized tobramycin for early treatment of Pseudomonas colonization in cystic fibrosis. Pediatr Pulmonol 25:88-92.
161. Yang Y, Devor DC, Engelhardt JF, Ernst SA, Strong TV, Collins FS, Cohn JA, Frizzell RA, Wilson JM (1993) Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR. Hum Molec Genet 2:1253-1261.
162. Zeiher BG, Eichwald E, Zabner J, Smith JJ, Puga AP, McCray PB Jr, Capecchi MR, Welsh MJ, Thomas KR (1995) A mouse model for the delta-F508 allele of cystic fibrosis. J Clin Invest 96:2051-2064.
163. Zeitlin PL (1998) Therapies directed at the basic defect in cystic fibrosis. Clin Chest Med 19:515-525.
164. Zeitlin PL, Crawford I, Lu L, Woel S, Cohen ME, Donowitz M, Montrose MH, Hamosh A, Cutting GR, Gruenert D, Huganir R, Maloney P, Guggino WB (1992) CFTR protein expression in primary and cultured epithelia. Proc Nat Acad Sci 89:344-347.
165. Zielenski J, Bozon D, Kerem B, Markiewicz D, Dune P, Rommens JM, Tsui LC (1991) Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 10:229-235.
166. Zielenski J, Corey M, Rozmahel R, Markiewicz D, Aznarez I, Casals T, Larriba S, Mercier B, Cutting G, Macek M, Placio A, Langfelder E, Henshaw C, Marshall B, DeCelie-Germana J, Claustres M, Nowakowska A., Bal J, Ferec C, Estivill X, Dune P, Tsui L-C (1999) Detection of a cystic fibrosis modifier (CFM1) locus for meconium ileus on human chromosome 19q13. unpublished data; submitted Dec. 1998.
167. Zielenski J, Patrizio P, Corey M, Handelin B, Markeiwicz D, Asch R, Tsui LC (1995) CFTR gene variant for patients with congenital absence vas deferens. Am J Hum Genet 57:958-960.
168. Zielenski J, Tsui LC (1995) Cystic fibrosis: genotypic and phenotypic variations. Ann Rev Genet 29:777-807.